BREAKTHROUGH IN NEUROREGENERATION

NeuExcell's ATN ASTROCYTES TO NEURONSTM Platform aims at disrupting the dogma that neurons are irreplaceable.

The dogma of neuroregeneration has been that neurons cannot be repaired or replaced.  NeuExcell's innovative technology challenges that doctrine and focuses on regenerating neural tissue.  While neurons cannot divide to regenerate themselves, glial cells are a renewable source for generating neurons at the site of injury.  Our ATN ASTROCYTES TO NEURONSTM platform uses gene therapy to deliver specific transcription factors to glial cells in the brain, which converts these cells into functional and fully integrated neurons. We have generated proof of concept in rodents as well as in NHP with robust pre-clinical data for 3 lead indications, glioblastoma (GBM), stroke, and Alzhermer's Disease (AD).  

Milestones

Milestones

  • 2016

    NeuExcell Formed at Penn State University Tech Incubator

  • 2019

    NeuExcell Builds Management Team

  • 2021

    $10+ Million Series Pre-A Round Raised

  • 2023

    Raised Series Pre-A+ Round of $15+ Million

  • 2024

    First In Human Clinical Trial Initiated for GBM

PROPRIETARY PLATFORM

PROPRIETARY PLATFORM